Immunophenotype of Peripheral Blood Mononuclear Cells to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma

What this Trial Is About

Researchers are evaluating a simple and reproducible blood test called a cytofluorimetric assay to help predict how patients with hepatocellular carcinoma (HCC), a type of liver cancer, respond to immunotherapy. This test aims to complement imaging studies by identifying early treatment responses, distinguishing true progression from pseudo-progression, and predicting when the treatment may stop being effective. The study also examines specific immune cell markers and gene expression in blood cells to understand differences between patients who respond to treatment and those who do not. Participants will receive immunochemotherapy combined with antiangiogenic drugs as part of their treatment. The study measures immune cells in the blood, including CD8+, PD1+, PD-L1+, CTLA4+, LAG3+ lymphocytes, and circulating granulocytes, to assess their role in treatment response. Additionally, transcriptomic (RNA) analyses of peripheral blood mononuclear cells will be performed and validated in independent groups to identify biomarkers linked to therapy outcomes. Throughout the study, participants will undergo laboratory tests and follow-up visits at the study center. Researchers will collect blood samples to perform immunophenotypic testing and gene expression analysis at baseline and during treatment. The main outcome is to find predictive biomarkers of response to immunotherapy within the first three months. The study requires written informed consent and continuous monitoring to ensure safety and accurate data collection during treatment and follow-up.

Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma